HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) clinical trials

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

This study is testing a new medicine, HMB-002, for people with Von Willebrand Disease (VWD). It's looking at how safe it is, how the body uses it, and if it helps reduce bleeding. It's for adults aged 18-64.